Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure.

This study characterized the pharmacokinetics of novel 100 mg levofloxacin dispersible tablets in 24 children aged <5 years with household MDR-TB exposure. Data was pooled with previously published data from children (n=109) with MDR-TB receiving adult (250 mg) levofloxacin tablets, using nonlinear mixed-effects modelling. The adult 250 mg tablets had 41% lower bioavailability compared to the novel dispersible tablets, resulting in much higher exposures with the dispersible tablets with the same mg/kg dose.
PMID: 30670421 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - January 22, 2019 Category: Microbiology Authors: Garcia-Prats AJ, Purchase SE, Osman M, Draper HR, Schaaf HS, Wiesner L, Denti P, Hesseling AC Tags: Antimicrob Agents Chemother Source Type: research